Atopic Dermatitis

The study showed that both the nasal and skin microbiomes are associated with the severity of atopic dermatitis in children.

Data from 4 phase 3 trials suggest that all anatomic regions are equally responsive to dupilumab treatment in patients with moderate-to-severe atopic dermatitis.

The FDA has approved the use of Dupixent (dupilumab; Sanofi and Regeneron) to treat moderate-to-severe atopic dermatitis in adolescent patients 12–17 years old.

Gestational duration and Cesarean sections were associated with comorbid atopic dermatitis and food allergies in children, respectively.

Based on these results, the bleach bath did not display antibacterial properties by reducing the growth of the bacterial colony.

Data collection included socio-demographic variables, comorbidities, treatment-related clinical events, immunosuppressant usage, concomitant treatment, and adjustments in dose or type of immunosuppressant.

These findings indicate age-specific treatment approaches would likely benefit patients with atopic dermatitis.

Baricitinib, a Janus kinase inhibitor, is currently approved under the brand name Olumiant for the treatment of moderately-to-severely active rheumatoid arthritis.